<DOC>
	<DOCNO>NCT01631825</DOCNO>
	<brief_summary>- To investigate safety once-daily repeat transdermal administration SPM 962 within dose range 4.5 36.0 mg/day ( 54-week treatment period ) Parkinson 's disease ( PD ) patient treat concomitantly L-dopa multi-center , open-label uncontrolled study . - To investigate efficacy SPM 962 exploratory manner .</brief_summary>
	<brief_title>A Long-Term Extension Trial From SPM 962 Advanced Parkinson 's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subject complete precede trial 24308001 . Subject discontinue precede trial 24308001 . Subject serious adverse event association investigational drug rule trial 24308001 . Subject persistent serious adverse event baseline , observe association investigational drug rule trial 24308001 . Subject persistent confusion , hallucination , delusion excitation trial 24308001 . Subject abnormal behavior obsessivecompulsive disorder delusion 24308001 study . Subject show serious extensive application site reaction beyond application site 24308001 study . Subject orthostatic hypotension systolic blood pressure ( SBP ) &lt; = 100 mmHg decrease SBP spine stand position &gt; = 30 mmHg baseline . Subject history epilepsy , convulsion etc . trial 24308001 . Subject develop serious ECG abnormality baseline . Subject QTcinterval &gt; = 500 msec baseline subject increase QTcinterval &gt; = 60 msec baseline trial 24308001 QTcinterval &gt; 470 msec female &gt; 450 msec male baseline . Subject serum potassium level &lt; 3.5 mEq/L end taper period trial 24308001 . Subject total bilirubin &gt; = 3.0 mg/dL AST ( GOT ) ALT ( GPT ) great 2.5 time upper limit reference range ( ? 100 IU/L ) end period trial 24308001 . Subject BUN &gt; = 30 mg/dL serum creatinine &gt; = 2.0 mg/dl end taper period trial 24308001 . Subject plan pregnancy trial . Subject unable give consent . Subject judged inappropriate trial investigator reason .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>SPM 962</keyword>
	<keyword>rotigotine</keyword>
	<keyword>Parkinson 's disease</keyword>
	<keyword>concomitant use L-dopa</keyword>
</DOC>